Product
INBRX-101
2 clinical trials
2 indications
Indication
Alpha-1 Antitrypsin DeficiencyClinical trial
This is a Phase 2, Single Arm, Open Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema.Status: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of INBRX-101 Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) EmphysemaStatus: Recruiting, Estimated PCD: 2025-05-01